This Page Is Inserted by IFW Operations and is not a part of the Official Record

BEST AVAILABLE IMAGES


Defective images within this document are accurate representations of the original documents submitted by the applicant.

Defects in the images may include (but are not limited to):

- BLACK BORDERS
- TEXT CUT OFF AT TOP, BOTTOM OR SIDES
- FADED TEXT
- ILLEGIBLE TEXT
- SKEWED/SLANTED IMAGES
- COLORED PHOTOS
- BLACK OR VERY BLACK AND WHITE DARK PHOTOS
- GRAY SCALE DOCUMENTS

IMAGES ARE BEST AVAILABLE COPY.

As rescanning documents will not correct images, please do not report the images to the Image Problem Mailbox.



 R_{3} R_{2} R_{1} $(CR_{5}R_{6})_{m}$ $(R_{9})_{n}$ $(R_{9})_{n}$ (I)

wherein

10003015 11010

5

10

15

20

A is C, CR_{10} or N;

X is CR_{11} or N;

Y is CR_7 or N with the proviso that when X is N, then Y must be CR_7 ;

R₁ is H, C₁-C₆alkylcarbonyl, C₁-C₆alkylcarbonyloxy or an C₁-C₆alkyl, C₁-C₆alkenyl, C₁-C₆alkynl or cycloheteroalkyl group each optionally substituted;

 R_2 , R_3 , R_4 , R_5 and R_6 are each independently H, halogen, OH or an optionally substituted C_1 - C_6 alkyl group;

R₇ and R₁₁ are each independently H, halogen or an C₁-C₆alkyl, aryl, heteroaryl or C₁-C₆alkoxy group each optionally substituted;

R₈ is an C₁-C₆alkyl, aryl or heteroaryl group each optionally substituted;

Sub

 R_9 is H, halogen or an C_1 - C_6 alkyl, C_1 - C_6 alkoxy, C_1 - C_6 alkenyl, aryl or heteroaryl group each optionally substituted;

 R_{10} is H, OH or an optionally substituted $C_1\text{-}C_6alkoxy$ group;

m is an integer of 1, 2 or 3;
n is 0 or an integer of 1, 2 or 3; and
---- represents a single bond or a double bond; or
a pharmaceutically acceptable salt thereof.

10


- 2. The compound according to claim 1 wherein A is N and m is 2.
- 3. The compound according to claim 1 wherein R_8 is an optionally substituted phenyl group.
 - 4. The compound according to claim 1 wherein $R_2, \\ R_3, \ R_4, \ R_5 \ \text{and} \ R_6 \ \text{are} \ \text{H}.$

- 5. The compound according to claim 2 wherein R_1 is H or a C_1 - C_6 alkyl or cycloheteroalkyl group each optionally substituted.
- 6. The compound according to claim 5 selected from 25 the group consisting of:
 - 1-(phenylsulfonyl)-4-piperazih-1-yl-1H-indole;
 - 1-[(2-bromophenyl)sulfonyl]-4-piperazin-1-yl-1H-indole;
 - 1-[(6-chloroimidazo[2,1-b][1,3]thiazol-5-yl)sulfonyl]-4piperazin-1-yl-1H-indole;
- 30 1-[(3,4-dimethoxyphenyl)sulfonyl]-4-piperazin-1-yl-1Hindole;

```
1-\((5-chloro-3-methyl-1-benzothien-2-yl)sulfonyl]-4-
               piperazin-1-yl-1H-indole;
          1-[(4-\promophenyl)sulfonyl]-4-piperazin-1-yl-1H-indole;
          1-[(5-bkomothien-2-yl)sulfonyl]-4-piperazin-1-yl-1H-
               indole;
      5
          1-[(4,5-diahlorothien-2-yl)sulfonyl]-4-piperazin-1-yl-1H-
               indole:
          methyl 4-[(4-piperazin-1-yl-1H-indol-1-yl)sulfonyl]phenyl
               ether;
10
          4-piperazin-1-yl-1-{[4-
               (trifluoromethoxy) phenyl] sulfonyl}-1H-indole;
          4-(4-benzylpiperazin-1-yl)-1-(phenylsulfonyl)-1H-indole;
          4-(4-benzylpiperazin 1-yl)-1-[(2-bromophenyl)sulfonyl]-
               1H-indole;
     15
         4-(4-benzylpiperazin-1-\forall 1)-1-[(6-chloroimidazo[2,1-
TOICI
               b] [1,3]thiazol-5-yl\sulfonyl]-1H-indole;
         4-(4-benzylpiperazin-1-yl)-1-[(3,4-
               dimethoxyphenyl)sulforyl]-1H-indole;
         4-[4-(3-methoxybenzyl)piperazin-1-yl]-1-(phenylsulfonyl)-
     20
               1H-indole;
         1-(phenylsulfonyl)-4-[4-(pyrid\n-4-ylmethyl)piperazin-1-
              yl]-1H-indole;
         1-(phenylsulfonyl)-4-[4-(pyridin->-ylmethyl)piperazin-1-
              yl]-1H-indole;
     25
         1-[(2-bromophenyl)sulfonyl]-4-[4-(3)]
              methoxybenzyl)piperazin-1-yl]-1\(\hat{1}\)-indole;
         1-[(2-bromophenyl)sulfonyl]-4-[4-(pyridin-4-
              ylmethyl)piperazin-1-yl]-1H-indole\;
         1-[(2-bromophenyl)sulfonyl]-4-[4-(pyridin-3-
    30
              ylmethyl)piperazin-1-yl]-1H-indole;
         1-(phenylsulfonyl)-5-piperazin-1-yl-1H-indazole;
```

```
%phenylsulfonyl)-6-piperazin-1-yl-1H-indazole;
    1-[(α-bromophenyl)sulfonyl]-6-piperazin-1-yl-1H-indazole;
    1-[(4-\promophenyl)sulfonyl]-5-piperazin-1-yl-1H-indazole;
    1-[(4-bromophenyl)sulfonyl]-6-piperazin-1-yl-1H-indazole;
    1-[(5-bromothien-2-yl)sulfonyl]-5-piperazin-1-yl-1H-
 5
         indazole;
    1-[(5-bromothien-2-yl)sulfonyl]-6-piperazin-1-yl-1H-
         indazole:
    1-[(4-fluorophenyl)sulfonyl]-5-piperazin-1-yl-1H-
10
         indazole;
    1-[(4-fluorophenyl)sulfonyl]-6-piperazin-1-yl-1H-
         indazole:
    methyl 4-[(5-piperazin\1-yl-1H-indazol-1-
         yl) sulfonyl] phenyl ether;
15
    1-phenylsulfonyl-4-(4-propylpiperazin-1-yl)-1H-indazole;
    1-phenylsulfonyl-4-piperazin-1-yl-1H-indazole;
    1-phenylsulfonyl-4-(4-phenethylpiperazin-1-yl)-1H-
         indazole;
    1-phenylsulfonyl-4-[4-(3-phenylpropyl)-piperazin-1-yl]-
20
         1H-indazole; and
    the pharmaceutically acceptable salts thereof.
```

7. A method for the treatment of a disorder of the central nervous system related to or affected by the 525 HT6 receptor in a patient in need thereof which comprises administering to said patient a therapeutically effective amount of a compound of formula I.



5ch = A2

5

10

15

20

wherein

A is C, CR_{10} or N;

X is CR₁₁ or W;

Y is CR_7 or N with the proviso that when X is N, then Y must be CR_7 ;

R₁ is H, C₁-C₆alkylcarbonyl, C₁-C₆alkylcarbonyloxy or an C₁-C₆alkyl, C₁-C₆alkenyl, C₁-C₆alkynl or cycloheteroalkyl group each optionally substituted;

 R_2 , R_3 , R_4 , R_5 and R_6 are each independently H, halogen, OH or an optionally substituted C_1 - C_6 alkyl group;

 R_7 and R_{11} are each independently H, halogen or an C_1 - C_6 alkyl, aryl, heteroaryl or C_1 - C_6 alkoxy group each optionally substituted;

R₈ is an C₁-C₆alkyl, aryl or heteroaryl group each optionally substituted;

R₉ is H, halogen or an C₁-C₆alkyl, C₁-C₆alkoxy, C₁-C₆alkenyl, aryl or heteroaryl group each optionally substituted;

 R_{10} is H, OH or an optionally substituted C_1 - C_6 alkoxy group;

sub Az

m is an integer of 1, 2 or 3;

n is 0 or an integer of 1, 2 or 3; and

____ represents a single bond or a double bond; or a pharmaceutically acceptable salt thereof.

5

8. The method according to claim 7 wherein said disorder is a motor disorder, anxiety disorder or cognitive disorder.

HODOWOLL SUN AV 15

9. The method according to claim 7 wherein said disorder is schizophrenia or depression.

- 10. The method according to claim 8 wherein said cognitive disorder is a neurodegenerative disorder.
- 11. The method according to claim 10 wherein said neurodegenerative disorder is Alzheimer's disease or Parkinson's disease

20

12. A pharmaceutical composition which comprises a pharmaceutically acceptable carrier and an effective amount of a compound of formula I.

$$R_{3}$$
 R_{2}
 R_{1}
 R_{3}
 R_{4}
 R_{4}
 R_{4}
 R_{4}
 R_{5}
 R_{2}
 R_{1}
 R_{2}
 R_{1}
 R_{2}
 R_{3}
 R_{4}
 R_{5}
 R_{5}
 R_{7}
 R_{1}
 R_{2}
 R_{3}
 R_{4}
 R_{4}
 R_{5}
 R_{5}
 R_{7}
 R_{7

```
wherein
                 A\is C, CR_{10} or N;
                 X is CR_{11} or N;
                 Y is \C R_7 or N with the proviso that when X is N, then
                       Y must be CR7;
       5
                 R_1 is H, C_1-C<sub>6</sub>alkylcarbonyl, C_1-C<sub>6</sub>alkylcarbonyloxy or
                       an C_1-O_6alkyl, C_1-C_6alkenyl, C_1-C_6alkynl or
                       cycloheteroalkyl group each optionally
                       substituted;
R_2, R_3, R_4, R_5 and R_6 are each independently H,
      10
                       halogen, OH or an optionally substituted C1-
                       Calkyl group;
                 R_7 and R_{11} are each independently H, halogen or an C_1-
                       C<sub>6</sub>alkyl, aryl, heter∂aryl or C<sub>1</sub>-C<sub>6</sub>alkoxy group
each optionally substituted;
      15
                 R<sub>8</sub> is an C<sub>1</sub>-C<sub>6</sub>alkyl, aryl or heteroaryl group each
                       optionally substituted;
                 R_9 is H, halogen or an C_1-C_6alkyl, C_1-C_6alkoxy, C_1-
                       Calkenyl, aryl or heteroaryl group each
                       optionally substituted;
      20
                 R<sub>10</sub> is H, OH or an optionally substituted C<sub>1</sub>-C<sub>6</sub>alkoxy
                       group;
                 m is an integer of 1, 2 or 3;
                 n is O or an integer of 1, 2 or 3; and
                 ---- represents a single bond or a double bond; or
      25
           a pharmaceutically acceptable salt thereof.
```

^{13.} The composition according to claim 12 wherein A is N and m is 2.

- 14. The composition according to claim 12 wherein R_8 is an optionally substituted phenyl group.
- 15. The composition according to claim 12 wherein 5 R_2 , R_3 , R_4 , R_5 and R_6 are H.
 - 16. The composition according to claim 13 wherein R_1 is H or a C_1 -Calkyl or cycloheteroalkyl group each optionally substituted.
 - 17. The composition according to claim 16 having a compound of formula I selected from the group consisting of:
 - 1-(phenylsulfonyl)-4-piperazin-1-yl-1H-indole;
- 15 1-[(2-bromophenyl)sulfonyl]-4-piperazin-1-yl-1H-indole;
 - 1-[(6-chloroimidazo[2,1\b][1,3]thiazol-5-yl)sulfonyl]-4piperazin-1-yl-1H-indole;
 - 1-[(3,4-dimethoxyphenyl)sulfonyl]-4-piperazin-1-yl-1H-indole;
- 20 1-[(5-chloro-3-methyl-1-benzothien-2-yl)sulfonyl]-4piperazin-1-yl-1H-indole;
 - 1-[(4-bromophenyl)sulfonyl]-4-Riperazin-1-yl-1H-indole;
 - 1-[(5-bromothien-2-yl)sulfonyl] \d-piperazin-1-yl-1H-indole;
- 25 1-[(4,5-dichlorothien-2-yl)sulfonyl]-4-piperazin-1-yl-1H-indole;
 - methyl 4-[(4-piperazin-1-yl-1H-indol\1-yl)sulfonyl]phenyl ether;
 - 4-piperazin-1-yl-1-{[4-
- 30 (trifluoromethoxy)phenyl]sulfonyl}\[1H-indole;
 4-(4-benzylpiperazin-1-yl)-1-(phenylsulfonyl)-1H-indole;

```
(4-benzylpiperazin-1-yl)-1-[(2-bromophenyl)sulfonyl]-
               1H-indole;
         4-(4-benzylpiperazin-1-yl)-1-[(6-chloroimidazo[2,1-
               b] [1,3]thiazol-5-yl)sulfonyl]-1H-indole;
         4-(4-benzylpiperazin-1-yl)-1-[(3,4-
      5
               dimethoxyphenyl) sulfonyl] -1H-indole;
          4-[4-(3-methoxybenzyl)piperazin-1-yl]-1-(phenylsulfonyl)-
               1H-indole;
          1-(phenylsulfonyl)-4-[4-(pyridin-4-ylmethyl)piperazin-1-
loosols licato
     10
               yl]-1H-indale;
          1-(phenylsulfonyl)-4-[4-(pyridin-3-ylmethyl)piperazin-1-
               yl]-1H-indole \
          1-[(2-bromophenyl)sulfonyl]-4-[4-(3-
               methoxybenzyl)piperazin-1-yl]-1H-indole;
          1-[(2-bromophenyl)sulfonyl]-4-[4-(pyridin-4-
     15
               ylmethyl)piperazin-\(\frac{1}{2}\)-yl]-1H-indole;
          1-[(2-bromophenyl)sulfonyl]-4-[4-(pyridin-3-
               ylmethyl)piperazin-1-yll-1H-indole;
          1-(phenylsulfonyl)-5-piperazin-1-yl-1H-indazole;
     20
          1-(phenylsulfonyl)-6-piperazin-1-yl-1H-indazole;
          1-[(2-bromophenyl)sulfonyl]-6-piperazin-1-yl-1H-indazole;
          1-[(4-bromophenyl)sulfonyl]-5-piperazin-1-yl-1H-indazole;
          1-[(4-bromophenyl)sulfonyl]-6-piperazin-1-yl-1H-indazole;
          1-[(5-bromothien-2-yl)sulfonyl]-5-piperazin-1-yl-1H-
               indazole;
     25
          1-[(5-bromothien-2-yl)sulfonyl]-6-piperazin-1-yl-1H-
               indazole;
          1-[(4-fluorophenyl)sulfonyl]-5-piperazin,1-yl-1H-
               indazole;
          1-[(4-fluorophenyl)sulfonyl]-6-piperazin-1-yl-1H-
     30
               indazole;
```

methyl 4-[(5-piperazin-1-yl-1H-indazol-1-yl)sulfonyl]phenyl ether;

1-phenylsulfonyl-4-(4-propylpiperazin-1-yl)-1H-indazole;

1-phenylsulfonyl-4-piperazin-1-yl-1H-indazole;

5 1-phenylsulfonyl-4-(4-phenethylpiperazin-1-yl)-1Hindazole;

1-phenylsulfonyl-4-[4-(3-phenylpropyl)-piperazin-1-yl]1H-indazole; and

the pharmaceutically acceptable salts thereof.

18. A method for the preparation of a compound of formula I.

$$R_3$$
 R_2
 R_1
 R_4
 R_4
 R_4
 R_5
 R_6)_m
 R_9)n
 R_4
 R_9)n
 R_7

15 wherein

A is C, CR₁₀ or N;

X is CR₁₁ or N;

Y is CR_7 or N with the proviso that when X is N, then Y must be CR_7 ;

20 R₁ is C₁-C₆alkylcarbonyl, C₁-C₆alkylcarbonyloxy or an C₁-C₆alkyl, C₁-C₆alkenyl, C₁-C₆alkynl or cycloheteroalkyl group each optionally substituted;

10

15

 R_2 , R_3 , R_4 , R_5 and R_6 are each independently H, halogen, OH or an optionally substituted C_1 - C_6 alkyl group;

 R_7 and R_{11} are each independently H, halogen or an C_1 - C_6 alkyl, aryl, heteroaryl or alkoxy group each optionally substituted;

 R_8 is an C_1 - C_6 alkyl, aryl or heteroaryl group each optionally substituted;

 R_9 is H, halogen or an C_1 - C_6 alkyl, C_1 - C_6 alkoxy, C_1 - C_6 alkenyl, aryl or heteroaryl group each optionally substituted;

 R_{10} is H, OH or an optionally substituted C_1 - C_6 alkoxy group;

m is an integer of 1, 2 or 3;

n is 0 or an integer of 1, 2 or 3; and

____ represents a single bond or a double bond said method which comprises reacting a compound of formula Ia

$$R_3$$
 R_4
 R_4
 R_4
 R_4
 R_4
 R_9
 R_4
 R_9
 R_9
 R_9
 R_9

20

wherein A, X, R_2 , R_3 , R_4 , R_5 , R_6 , R_7 , R_8 , R_9 , R_9 , and n are as defined hereinabove for formula I with a compound R_1 -Hal

516 A2

wherein R_1 is as defined hereinabove for formula I and Hal is Cl, Br or I.

add A2/